Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

OBJECTIVES: Acquired resistance represents a bottleneck to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung cancer. Our study aimed to explore the efficacy of antiangiogenic‐based therapy in osimertinib‐resistant NSCLC patients and assess the efficacy of anlo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ya, Liu, Hongyu, Hu, Nana, Wang, Yanan, Yang, Zhengyu, Zhang, Junqiang, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469739/
https://www.ncbi.nlm.nih.gov/pubmed/37387596
http://dx.doi.org/10.1002/cam4.6232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469739/
https://www.ncbi.nlm.nih.gov/pubmed/37387596
http://dx.doi.org/10.1002/cam4.6232

Ejemplares similares